Dasatinib (Sprycel)
General information
Class/mechanism: Tyrosine kinase inhibitor of BCR-ABL, the SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFR. Believed to bind to multiple conformations of the ABL kinase.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Dasatinib (Sprycel) patient drug information (Chemocare)[3]
- Dasatinib (Sprycel) patient drug information (UpToDate)[4]
Regimens
Standard format will be:
<acronym (if any)> <generic drug1, generic drug2, generic drug3, etc.> (disease)